Doctors have long struggled to treat advanced uterine cancer once standard therapies stop working.
For many women, surgery and chemotherapy can successfully remove or control the disease at first. But if the cancer returns or becomes resistant to treatment, survival chances often become much lower.
Now, a new study from the Yale School of Medicine has revealed that a drug already approved for breast cancer could help patients with hard-to-treat uterine cancer. The findings were published in the journal Clinical Cancer Research and are attracting attention because they may lead to one of the biggest advances in uterine cancer treatment in years.
Uterine cancer develops in the tissues of the uterus, most often in the inner lining called the endometrium. It is the most deadly cancer affecting the female reproductive system.
While many people think of cervical cancer or ovarian cancer as more dangerous, uterine cancer actually causes a large number of deaths each year because it is often discovered later and treatment choices remain limited.
According to estimates from the National Institutes of Health, around 68,000 Americans are expected to be diagnosed with uterine cancer in 2026. About 14,400 people are expected to die from the disease. Experts also warn that the number of cases may continue rising sharply in the future.
One reason for this increase is the lack of routine screening. Unlike breast cancer, which can often be found early with mammograms, or colon cancer, which can be detected through colonoscopies, there is currently no standard screening test for uterine cancer.
Researchers have therefore focused heavily on finding better treatments, especially for patients whose cancer no longer responds to surgery or chemotherapy.
The new study examined a drug called sacituzumab govitecan. This medicine belongs to a newer generation of cancer therapies known as targeted chemotherapy. Instead of attacking all fast-growing cells throughout the body, targeted treatments are designed to seek out specific markers found mainly on cancer cells.
Years ago, Yale researchers discovered that many uterine cancer cells contain large amounts of a protein called Trop-2. Scientists realized this protein could act like a target for a specially designed drug.
Sacituzumab govitecan uses an antibody that recognizes the Trop-2 protein. The antibody carries chemotherapy directly to the tumor cells. Once attached, it releases the cancer-fighting medicine into the tumor itself.
This targeted approach may help reduce some of the severe side effects linked to traditional chemotherapy, which can damage healthy tissues along with cancer cells.
The drug was originally developed through collaboration between Yale researchers and the pharmaceutical company Immunomedics, which is now part of Gilead Sciences. After successful breast cancer studies, the U.S. Food and Drug Administration approved the drug in 2023 for some patients with advanced breast cancer.
The latest study wanted to see whether the same treatment could also help women with advanced uterine cancer.
Researchers enrolled 50 patients whose uterine cancer had already failed to respond to standard treatments. All participants had previously undergone surgery and chemotherapy, but their disease continued progressing.
Patients received two doses of sacituzumab govitecan every 21 days. Doctors then closely monitored changes in tumor size.
The results surprised researchers. Fourteen patients experienced tumor shrinkage of at least 30%. More than 70% showed some reduction in tumor growth overall.
These findings are considered very encouraging because late-stage uterine cancer treatments often work poorly. In many cases, standard chemotherapy at this stage helps fewer than 15% of patients.
Lead researcher Dr. Alessandro Santin explained that patients with treatment-resistant uterine cancer urgently need new options. Many women reach a point where there are almost no effective therapies left.
The study also found that the drug’s side effects were generally manageable. Some patients developed diarrhea, reduced white blood cell counts, and bone marrow-related problems. However, doctors were usually able to control these issues with supportive care.
Importantly, researchers noted that the treatment appeared less toxic overall than many standard chemotherapy drugs. This may improve quality of life for patients already dealing with advanced cancer and repeated treatments.
The promising results have now led to plans for a much larger Phase III clinical trial. This next stage will compare sacituzumab govitecan directly with regular chemotherapy to see whether it truly offers better survival and tumor control.
Cancer experts say the study reflects a major shift happening throughout modern medicine. For decades, chemotherapy treated many cancers in a similar way, even though tumors can behave very differently from person to person.
Now, researchers increasingly focus on personalized medicine. By identifying specific proteins or genetic markers inside tumors, scientists can design treatments that attack cancer more precisely.
Drugs like sacituzumab govitecan are part of this growing movement toward targeted therapy. Researchers believe these approaches may eventually replace many older chemotherapy methods.
The study still has some important limitations. Because only 50 patients were involved, scientists cannot yet guarantee the same results will happen in larger populations. Long-term survival benefits also still need further study.
Even so, the findings represent a hopeful development for women facing one of the most difficult forms of reproductive cancer. If future studies confirm the results, this drug could become a valuable treatment for patients who currently have very few options left.
Looking at the research overall, the study appears especially important because it demonstrates how understanding cancer biology can lead to more effective treatments.
Targeting the Trop-2 protein may allow doctors to deliver chemotherapy more directly into tumors while reducing damage to healthy cells. Although more research is needed, the strong tumor shrinkage rates seen in this trial suggest that targeted therapies may significantly improve outcomes for patients with resistant uterine cancer in the future.
If you care about cancer, please read studies that artificial sweeteners are linked to higher cancer risk, and how drinking milk affects risks of heart disease and cancer.
For more health information, please see recent studies about the best time to take vitamins to prevent heart disease, and results showing vitamin D supplements strongly reduces cancer death.
Source: Yale School of Medicine.
